Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Predicting Reaction Outcomes02:24

Predicting Reaction Outcomes

10.9K
Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.9K
Outcomes of Glycolysis01:13

Outcomes of Glycolysis

107.3K
Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
107.3K
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.3K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.3K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.4K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.4K
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

814
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
814
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

4.0K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association.

Stroke·2026
Same author

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.

Neuro-oncology·2026
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025
Same author

Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.

Acta neuropathologica·2025
Same author

Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma.

Neuro-oncology·2025
Same author

Liquid biopsy in the diagnosis of primary brain tumors.

Advances in cancer research·2025

Related Experiment Video

Updated: Feb 5, 2026

Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience
10:17

Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience

Published on: November 15, 2024

1.7K

Improving outcomes in primary CNS lymphoma.

Maya S Graham1, Lisa M DeAngelis1

  • 1Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Best Practice & Research. Clinical Haematology
|September 15, 2018
PubMed
Summary

High-dose methotrexate and consolidation therapy have improved outcomes for primary central nervous system lymphoma (PCNSL). Further research into optimal regimens and biotherapies aims to achieve cures for more patients with this aggressive brain cancer.

Keywords:
Consolidation chemotherapyElderlyInduction chemotherapyPrimary central nervous system lymphomaPrimary refractory diseaseTargeted therapy

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K

Related Experiment Videos

Last Updated: Feb 5, 2026

Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience
10:17

Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience

Published on: November 15, 2024

1.7K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K

Area of Science:

  • Neuro-oncology
  • Hematology
  • Clinical Trials

Background:

  • Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain cancer with a historically poor prognosis.
  • Recent advances in high-dose methotrexate induction and consolidation therapies have significantly improved patient outcomes.
  • Despite progress, durable remission remains a challenge, with approximately half of patients not achieving long-term disease control.

Purpose of the Study:

  • To review current treatment strategies for PCNSL, highlighting advancements and persistent challenges.
  • To explore the potential of novel therapeutic approaches, including biotherapies, for PCNSL management.
  • To identify future research directions for optimizing treatment and improving cure rates in PCNSL.

Main Methods:

  • This review synthesizes findings from recent clinical studies and literature on PCNSL treatment.
  • It analyzes the efficacy and limitations of current induction and consolidation regimens.
  • The review also discusses emerging biotherapeutic strategies and their potential role in PCNSL therapy.

Main Results:

  • High-dose methotrexate-based induction regimens have become a cornerstone of PCNSL treatment.
  • Consolidation therapies further enhance treatment efficacy, leading to improved survival rates.
  • Significant challenges persist in achieving durable remissions and cures for all PCNSL patients.

Conclusions:

  • Optimizing induction and consolidation regimens is crucial for improving PCNSL outcomes.
  • Biotherapies hold promise as a future treatment modality for PCNSL.
  • Continued research into combined treatment strategies is essential to increase the cure rate for PCNSL.